Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis

By sjmartinez • June 23, 2024

Armstrong AW, Park SH, Patel V, Nicolas P, Wang WJ, Colombo MJ, Chirikov V. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis. Dermatol Ther (Heidelb). 2024 Jun 22. doi: 10.1007/s13555-024-01201-4. Epub ahead of print. PMID: 38907877.

Tags: apremilast, cumulative clinical benefit, Dermatology, deucravacitinib, Oral treatments, psoriasis, Publications, Small molecules

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R,[...]

Exacerbation of bullous systemic lupus erythematosus with erythema gyratum repens-like pattern following dupilumab

Santiago Mangual KP, Truong A, Mo J, Liu J, Khaligi MA, Haussmann A, Razmjou AA, Holland V, Cheng K. Exacerbation of bullous systemic lupus erythematosus[...]

Chronic companions: An updated national cross-sectional study of metabolic syndrome comorbidities in outpatient visits for hidradenitis suppurativa

Ma EJ, Roberts AM, Chou P, Katz A, Jeong CY, Nong Y, Ochoa MT, Armstrong AW. Chronic companions: An updated national cross-sectional study of metabolic[...]